Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

ClinicalTrials.gov ID: NCT02058563

Public ClinicalTrials.gov record NCT02058563. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762)

Study identification

NCT ID
NCT02058563
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
996 participants

Conditions and interventions

Interventions

  • Priorix® Biological
  • Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine Biological

Biological

Eligibility (public fields only)

Age range
7 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2014
Primary completion
May 23, 2015
Completion
Sep 16, 2015
Last update posted
Jun 5, 2018

2014 – 2015

United States locations

U.S. sites
10
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35211
GSK Investigational Site Chandler Arizona 85224
GSK Investigational Site Mesa Arizona
GSK Investigational Site Miami Florida 33144
GSK Investigational Site Miami Florida 33176
GSK Investigational Site Chicago Illinois 60654
GSK Investigational Site Edina Minnesota 55435
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Cincinnati Ohio 45249
GSK Investigational Site San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02058563, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 5, 2018 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02058563 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →